PepGen Inc. (NASDAQ:PEPG) Insider Sells $168,439.40 in Stock

PepGen Inc. (NASDAQ:PEPG) insider Michelle L. Mellion sold 9,260 shares of PepGen stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $18.19, for a total value of $168,439.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michelle L. Mellion also recently made the following trade(s):

• On Tuesday, June 11th, Michelle L. Mellion sold 500 shares of PepGen stock. The shares were sold at an average price of $18.04, for a total value of $9,020.00.

PepGen Stock Up 1.4 %

Shares of PEPG stock traded up $0.23 during mid-day trading on Wednesday, hitting $17.00. 115,500 shares of the stock were exchanged, compared to its average volume of 100,051. The firm has a fifty day moving average of $14.72 and a 200 day moving average of $12.33. The company has a market cap of $551.14 million, a PE ratio of -5.27 and a beta of 1.76. PepGen Inc. has a 52-week low of $3.72 and a 52-week high of $18.72.

PepGen (NASDAQ:PEPG) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.11. Equities analysts predict that PepGen Inc. will post -2.87 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on PEPG shares. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of PepGen in a report on Wednesday, May 15th. Wedbush reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of PepGen in a report on Wednesday, May 15th.

Institutional Trading of PepGen

A number of institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC purchased a new position in PepGen in the 1st quarter valued at $30,000. Artal Group S.A. acquired a new stake in shares of PepGen in the first quarter valued at about $2,940,000. Adage Capital Partners GP L.L.C. raised its position in shares of PepGen by 18.3% in the third quarter. Adage Capital Partners GP L.L.C. now owns 680,000 shares of the company’s stock valued at $3,454,000 after buying an additional 105,000 shares during the last quarter. Vanguard Group Inc. raised its position in shares of PepGen by 68.0% in the first quarter. Vanguard Group Inc. now owns 850,445 shares of the company’s stock valued at $12,502,000 after buying an additional 344,266 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of PepGen by 18.1% in the first quarter. Janus Henderson Group PLC now owns 1,166,642 shares of the company’s stock valued at $17,225,000 after buying an additional 178,438 shares during the last quarter. 58.01% of the stock is owned by institutional investors and hedge funds.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.